e-learning
resources
Munich 2014
Sunday, 07.09.2014
ILDs 1
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis
R. Yao, Y. Cao, Y. R. He, Z. Zeng, Z. A. Liang (Chengdu, China)
Source:
International Congress 2014 – ILDs 1
Session:
ILDs 1
Session type:
Thematic Poster Session
Number:
733
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Yao, Y. Cao, Y. R. He, Z. Zeng, Z. A. Liang (Chengdu, China). LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis. Eur Respir J 2014; 44: Suppl. 58, 733
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO
Source: International Congress 2014 – ILDs 6
Year: 2014
Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling
Source: International Congress 2014 – ILDs 4
Year: 2014
Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014
Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014
Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort
Source: International Congress 2014 – ILDs 4
Year: 2014
Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 2
Year: 2014
Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis
Source: International Congress 2014 – ILDs 5
Year: 2014
Lung
18
F-FDG uptake correlates with lung function alteration in patients with IPF
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014
Pirfenidone and BIBF1120 regulate properties of myofibroblasts
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
LATE-BREAKING ABSTRACT: Age-related PINK1 deficiency promotes mitochondria dysfuntion, epithelial injury and fibrosis in the lung
Source: International Congress 2014 – Lung cell biology in injury and repair
Year: 2014
Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS
Source: International Congress 2014 – ILDs 4
Year: 2014
Transient elastography detection of early liver fibrosis in idiopathic pulmonary fibrosis patients
Source: International Congress 2014 – ILDs 2
Year: 2014
Parenchymal cell populations involved in the development of fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014
Evolution of an interstitial lung disease MDT: 5.5 years of data
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept